Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Stock Information for Axcella Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Axcella Health Inc.

Axcella Announces Reverse Stock Split Effective September 19, 2023
Axcella Granted Patent for Long COVID Fatigue Treatment
Axcella Reports Second Quarter Financial Results and Provides Business Update
Axcella Reports First Quarter Financial Results and Provides Business Update
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.